Objective  To observe the short-term efficacy of selenium yeast combined with concurrent chemoradiotherapy for patients with stage ⅡB cervical cancer.

  Methods  One hundred and three cervical cancer patients were included and randomly divided into experimental group (n=50) and control group (n=53). The experimental group was given oral selenium yeast, while control group was given placebo, and both groups received concurrent chemoradiotherapy with cisplatin. After radiotherapy, the tumor lesion, myelosuppression, liver and kidney impairment were assessed by laboratory indicators and imaging results.

  Results  There were statistically significant difference in total effective rate between the two groups (P < 0.05). There was no significant difference in the incidence of bone marrow suppression, kidney injury, liver injury and other toxic and side effects between the experimental group and the control group (P>0.05).

  Conclusion  The short-term efficacy of selenium yeast tablets during concurrent chemoradiotherapy in patients with advanced cervical cancer is better than that of chemoradiotherapy alone.